On September 2, 2010
Allergan’s $600M Headache: DOJ Probe Could Spur FDA Scrutiny of Botox Data
Allergan (AGN)’s $600 million settlement with the Department of Justice — over illegally marketing Botox for unapproved uses such as headache — looks bad for the company’s pending application…
No tags for this post.
0 Comments